Feb 16, 2010 | Medical News
Meda publishes 2009 year-end report
"The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009." - The Group's net sales reached SEK 13,178 million , a 23% increase compared to the previous year.
FDA Sends Letter to Meda Regarding Promotions for Astelin
The FDA today posted on its website a letter sent to Meda Pharmaceuticals regarding a waiting room sign promoting allergy medication Astelin.
Also on Topix